M24-727 Luti Atopic Dermatitis

• Research type

  Research Study

• Full title

  A Phase 2 Multicenter Platform Trial of Targeted Immunomodulator Therapies for Moderate to Severe Atopic Dermatitis

• IRAS ID

  1011090

• Contact name

  Bernhard Dodell

• Contact email

  global-clinical-trials@abbvie.com

• Sponsor organisation

  AbbVie Deutschland GmbH & Co. KG

• Clinicaltrials.gov Identifier

  NCT06718101

• Research summary

  Atopic dermatitis (AD) is a skin condition that may cause arash and itching due to inflammation of the skin. The
  purpose of this study is to evaluate the clinical efficacy andsafety of single therapies and/or combination therapies formoderate to severe AD through multiple substudies.
  This study will consist of multiple sub-studies, Sub-Study 1will have a randomized, placebo controlled period 1
  followed by a lutikizumab treatment period 2 enrolling 80participants at a 1 to 1 ratio.
  In Sub-Study 1, participants will receive subcutaneous (SC)injections of lutikizumab or matching placebo every otherweek for 16 weeks followed by an additional 32 weeks ofsubcutaneous (SC) injections of lutikizumab every other
  week for a total of 52 weeks.

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  25/LO/0190

• Date of REC Opinion

  14 May 2025

• REC opinion

  Further Information Favourable Opinion